Publications by authors named "Alberto Bottini"

65Publications

Metastases from Occult Breast Cancer: A Case Report of Carcinoma of Unknown Primary Syndrome.

Case Rep Oncol 2020 Sep-Dec;13(3):1158-1163. Epub 2020 Sep 28.

Breast Unit, Humanitas Clinical and Research Center - IRCCS, Milan, Italy.

View Article and Find Full Text PDF
September 2020

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials.

Medicine (Baltimore) 2016 Oct;95(43):e4636

Section of Pharmacology and University Center DIFF-Drug Innovation Forward Future, Department of Molecular and Translational Medicine, University of Brescia, Brescia U.S. Terapia Molecolare e Farmacogenomica Radiotherapy Department, ASST Cremona, Cremona Section of Experimental Oncology, Department of Clinical and Experimental Medicine, University of Parma, Parma Unit of General Medicine, Azienda Ospedaliera "C. Poma" Presidio Ospedaliero di Pieve di Coriano, Mantova Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

View Article and Find Full Text PDF
October 2016

Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis.

Cancer Biol Ther 2016 09 14;17(9):883-8. Epub 2016 Jul 14.

b Unit of Molecular Therapy and Pharmacogenomic , AO Azienda Istituti Ospitalieri di Cremona , Cremona , Italy.

View Article and Find Full Text PDF
September 2016

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.

Clin Lung Cancer 2016 09 2;17(5):334-340. Epub 2016 Jun 2.

US Terapia Molecolare e Farmacogenomica, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

View Article and Find Full Text PDF
September 2016

Is it time for everolimus-based combination in castration-resistant prostate cancer?

Future Oncol 2016 Aug 2;12(16):1849-52. Epub 2016 Jun 2.

Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article and Find Full Text PDF
August 2016

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.

Eur J Cancer 2016 07 7;61:111-21. Epub 2016 May 7.

Molecular Therapy and Pharmacogenomic Unit, ASST di Cremona, Viale Concordia 1, 26100, Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.

View Article and Find Full Text PDF
July 2016

Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2016 Jun 8;102:82-8. Epub 2016 Apr 8.

Unit of Molecular Therapy and Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy; Department of Medical, Surgical and Neurosciences, Section of Advanced Surgical Oncology, University of Siena, Viale Bracci 11, 53100, Italy.

View Article and Find Full Text PDF
June 2016

Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.

Crit Rev Oncol Hematol 2016 May 27;101:12-20. Epub 2016 Feb 27.

Unit of molecular therapy and pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.

View Article and Find Full Text PDF
May 2016

Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient.

Anticancer Drugs 2016 Jun;27(5):470-3

aRadiotherapy Department, ASST Cremona bUnit of Molecular Therapy and Pharmacogenomics, ASST Cremona cDepartment of Molecular and Translational Medicine, Section of Pharmacology and University Center DIFF-Drug Innovation Forward Future, University of Brescia, Brescia dDepartment of Medical, Surgery, and Health Sciences, University of Trieste, Piazza Ospitale 1, Trieste, Italy.

View Article and Find Full Text PDF
June 2016

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Tumour Biol 2015 Sep 26;36(9):6653-65. Epub 2015 Aug 26.

U.O. Multidisciplinare di Patologia Mammaria, U.S. Terapia Molecolare e Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100, Cremona, Italy.

View Article and Find Full Text PDF
September 2015

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

J Natl Cancer Inst Monogr 2015 May;2015(51):90-6

Medical Oncology Unit (VA, ABe), University of Brescia, and Breast Unit (RP, LV, ELS) Spedali Civili Hospital, Brescia, Italy; U.O. Multidisciplinare di Patologia Mammaria, S.S. Terapia Molecolare e Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Cremona, Italy (DG, AR, MRC, LD, ABo); Departments of Radiation Oncology (TB) and Pathology (FS), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (MC); Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Milan, Italy (GC); Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine (MGD), and Medical Oncology Unit (SDC), Fondazione IRCCS - Istituto Nazionale Tumori, Milan, Italy (MGD); Academic Department of Biochemistry, Biochemical Endocrinology (MD), Department of Surgery, Breast Unit (PB), and The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research and Breast Unit (MD, GS), Royal Marsden Hospital, London, UK; Department of Pathology, Melbourne University, Parkville, Australia (SF); Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (ALH); Mount Vernon Cancer Centre, London, UK (AM); Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT (CH); Memorial Sloan Kettering Cancer Center, New York, NY (CAH); Division of Medical Oncology, Department of Hemato-oncology, IRCCS Policlinico 'San Matteo' Foundation, Pavia, Italy (PP); Dipartimento Medicina di Laboratorio, SC Anatomia ed Istocitopatologia Diagnostica e di Screening, A.O.U. Città della Salute e della Scienza di Torino, Università di Torino, Turin, Italy (AS); N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia (VS); German Breast Group & University of Frankfurt, Neu-Isenburg, Germany (GvM); The Russell H. Morgan Department of Radiology

View Article and Find Full Text PDF
May 2015

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

J Natl Cancer Inst Monogr 2015 May;2015(51):76-80

Rna Diagnostics Inc, Toronto, ON, Canada (KP, LP, AP); Department of Laboratory Medicine and Pathobiology and Department of Surgery, University of Toronto, Toronto, ON, Canada (KP, MT); Unita di Patologia Mammaria, Breasteast Unit, Azienda Ospedaliera Istituti Ospitaieri di Cremona, Cremona, Italy (DG, AB, MRC); Advanced Medical Research Institute of Canada, Sudbury, ON, Canada (BG, AP); Laurentian University, Sudbury ON, Canada (AP); Odette Cancer Centre, Sunnybrook Hospital, Toronto, ON, Canada (MT).

View Article and Find Full Text PDF
May 2015